New Avenue for Parkinson’s Disease Research

07-02-2019

Nearly 60,000 Americans are diagnosed with Parkinson’s disease each year, resulting in a $52 Billion annual economic burden to the U.S. government. Parkinson’s disease is typified by the toxic aggregation of a presynaptic protein called alpha-Synuclein. Research published recently by the Mattoo lab shows a role for the human Fic protein, HYPE, in preventing aggregation of alpha-Synuclein. This novel link between HYPE and alpha-Synuclein opens exciting new avenues of research towards developing therapeutics for Parkinson’s disease. 

Press Coverage links:

https://www.purdue.edu/newsroom/releases/2019/Q2/protein-shows-promise-in-treating-parkinsons-disease.html?mid=1361016110&ml=37571208

https://parkinsonsnewstoday.com/2019/06/13/hype-protein-treating-parkinsons-disease-study/

 

Manuscript link:

https://www.sciencedirect.com/science/article/pii/S0022283619302335?via%3Dihub